| Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts TK Karikari, TA Pascoal, NJ Ashton, S Janelidze, AL Benedet, ... The Lancet Neurology 19 (5), 422-433, 2020 | 1009 | 2020 |
| Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders S Palmqvist, S Janelidze, YT Quiroz, H Zetterberg, F Lopera, E Stomrud, ... Jama 324 (8), 772-781, 2020 | 991 | 2020 |
| Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia S Janelidze, N Mattsson, S Palmqvist, R Smith, TG Beach, GE Serrano, ... Nature medicine 26 (3), 379-386, 2020 | 975 | 2020 |
| Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity S Palmqvist, M Schöll, O Strandberg, N Mattsson, E Stomrud, H Zetterberg, ... Nature communications 8 (1), 1214, 2017 | 779 | 2017 |
| Plasma β-amyloid in Alzheimer’s disease and vascular disease S Janelidze, E Stomrud, S Palmqvist, H Zetterberg, D Van Westen, ... Scientific reports 6 (1), 26801, 2016 | 630 | 2016 |
| Plasma tau in Alzheimer disease N Mattsson, H Zetterberg, S Janelidze, PS Insel, U Andreasson, ... Neurology 87 (17), 1827-1835, 2016 | 519 | 2016 |
| CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease S Janelidze, H Zetterberg, N Mattsson, S Palmqvist, H Vanderstichele, ... Annals of clinical and translational neurology 3 (3), 154-165, 2016 | 480 | 2016 |
| Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder O Hansson, S Janelidze, S Hall, N Magdalinou, AJ Lees, U Andreasson, ... Neurology 88 (10), 930-937, 2017 | 445 | 2017 |
| Performance of fully automated plasma assays as screening tests for Alzheimer disease–related β-amyloid status S Palmqvist, S Janelidze, E Stomrud, H Zetterberg, J Karl, K Zink, T Bittner, ... JAMA neurology 76 (9), 1060-1069, 2019 | 408 | 2019 |
| Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography S Palmqvist, H Zetterberg, K Blennow, S Vestberg, U Andreasson, ... JAMA neurology 71 (10), 1282-1289, 2014 | 408 | 2014 |
| Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography S Palmqvist, N Mattsson, O Hansson, ADN Initiative Brain 139 (4), 1226-36, 2016 | 405* | 2016 |
| Discriminative accuracy of [18F] flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders R Ossenkoppele, GD Rabinovici, R Smith, H Cho, M Schöll, O Strandberg, ... Jama 320 (11), 1151-1162, 2018 | 404 | 2018 |
| Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease S Janelidze, E Stomrud, R Smith, S Palmqvist, N Mattsson, DC Airey, ... Nature communications 11 (1), 1683, 2020 | 365 | 2020 |
| Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures S Palmqvist, P Tideman, N Cullen, H Zetterberg, K Blennow, ... Nature medicine 27 (6), 1034-1042, 2021 | 364 | 2021 |
| Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease S Palmqvist, H Zetterberg, N Mattsson, P Johansson, ... Neurology 85 (14), 1240-1249, 2015 | 357 | 2015 |
| A multicentre validation study of the diagnostic value of plasma neurofilament light NJ Ashton, S Janelidze, A Al Khleifat, A Leuzy, EL van der Ende, ... Nature communications 12 (1), 3400, 2021 | 352 | 2021 |
| Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease JB Pereira, S Janelidze, R Smith, N Mattsson-Carlgren, S Palmqvist, ... Brain 144 (11), 3505-3516, 2021 | 334 | 2021 |
| CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease S Janelidze, N Mattsson, E Stomrud, O Lindberg, S Palmqvist, ... Neurology 91 (9), e867-e877, 2018 | 308 | 2018 |
| Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease S Palmqvist, PS Insel, E Stomrud, S Janelidze, H Zetterberg, B Brix, ... EMBO molecular medicine 11 (12), e11170, 2019 | 301 | 2019 |
| Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease R Ossenkoppele, R Smith, T Ohlsson, O Strandberg, N Mattsson, PS Insel, ... Neurology 92 (6), e601-e612, 2019 | 283 | 2019 |
Oskar HanssonProfessor of Neurology, Lund UniversityVerified email at med.lu.se
